Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Gains from Sales and Divestitures (2023 - 2025)

Profound Medical (PROF) has 3 years of Gains from Sales and Divestitures data on record, last reported at $171618.0 in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 24.98% year-over-year to $171618.0; the TTM value through Dec 2025 reached $171618.0, down 24.98%, while the annual FY2025 figure was $171618.0, 24.98% down from the prior year.
  • Gains from Sales and Divestitures reached $171618.0 in Q4 2025 per PROF's latest filing, up from $145448.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $228774.0 in Q4 2024 and bottomed at $10000.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 3 years is $97084.3, with a median of $79390.5 recorded in 2025.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 2187.74% in 2024, then dropped 24.98% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $10000.0 in 2023, then surged by 2187.74% to $228774.0 in 2024, then decreased by 24.98% to $171618.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $171618.0 in Q4 2025, $145448.0 in Q3 2025, and $13333.0 in Q2 2025.